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1258 The Journal of Thoracic and CardObjective: Patients with persistent pulmonary infections from mycobacterial disease
present a difficult clinical challenge. These individuals typically have poor pulmo-
nary function, malnutrition, and other comorbidities, and few guidelines exist
regarding optimal therapy. We report our experience with completion pneumonec-
tomy as part of a multidisciplinary treatment program for patients with recurrent,
persistent mycobacterial disease.
Methods: During a 9-year period, 26 consecutive patients underwent completion
pneumonectomy for mycobacterial disease. All patients underwent intensive, guided
preoperative antibiotic therapy and aggressive nutritional supplementation. Com-
plete surgical resection of the remaining destroyed or infected lung tissue was
performed, often through an extrapleural dissection with intrapericardial ligation of
vessels. Vascularized tissue flaps were used whenever possible to buttress the
bronchial stump closure. Postoperative management consisted of a multidisciplinary
approach, with ongoing antibiotic and nutritional therapy.
Results: The primary organisms were Mycobacterium avium complex (n  15),
Mycobacterium tuberculosis (n  5), Mycobacterium abscessus (n  3), Mycobac-
terium xenopi (n  2), and Mycobacterium chelonae (n  1). Operative mortality
was 23% (6/26): respiratory failure or adult respiratory distress syndrome in 2 cases,
sepsis in 2, bronchopleural fistula in 1, and pulmonary embolism in 1. Significant
morbidity occurred in 46% (12/26). Among the 17 long-term survivors, sputum
conversion or discontinuation of medications was achieved in 14 (82%). Mean
length of follow-up was 45 months (range 4-105 months).
Conclusion: Completion pneumonectomy remains an important component of
therapy in patients with mycobacterial disease who have had failure of previous
therapy. Although associated with significant risks, successful outcomes can be
achieved with an organized, multidisciplinary approach and careful postopera-
tive follow-up.
Pulmonary mycobacterial disease is a complex problem that is primarilytreated with medical therapy. However, some patients require surgical ther-apy for chronic, persistent disease. Indications for surgical intervention
include failure to thrive, persistent localized cavitary disease or destroyed lung,
persistent sputum positivity, hemoptysis, bronchopleural fistula (BPF), and bron-
chial stenosis.
Completion pneumonectomy is performed on a subgroup of these patients who
have undergone a previous pulmonary resection for a mycobacterial disease–related
process or for other underlying lung disease. Indications for completion pneumo-
nectomy are similar to those for primary resectional therapy. We report our expe-
rience with 26 patients undergoing completion pneumonectomy for chronic myco-
bacterial disease.
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We reviewed the hospital charts of 26 consecutive patients who
underwent completion pneumonectomy for chronic mycobacterial
infection at the University of Colorado Hospital between Septem-
ber 1994 and September 2003. The study was approved by the
University of Colorado Hospital’s institutional review board.
Completion pneumonectomy was defined as any procedure in
which any remaining lung was removed after a previous partial
resection. All patients were operated on by a single surgeon. There
were 19 female patients and 7 male patients. The average age was
55 years (range 21-73 years). Fifteen patients underwent right
completion pneumonectomy, and 11 patients underwent left com-
pletion pneumonectomy.
Previous operations included right upper lobectomy in 10 pa-
tients, right lower lobectomy in 1, right middle lobectomy in 1, left
upper lobectomy in 9, left lower lobectomy in 1, segmental or
wedge resection in 3, and bullectomy in 1. The indications for the
previous operation were resection for complications of mycobac-
terial disease in 15 patients, bronchiectasis-related pathology in 6,
bleb or bullous disease in 4, and complications of Wegener gran-
ulomatosis in 1. For the patients who had bronchiectatic disease as
an indication, it was unknown whether they had mycobacterial
infection at the time of initial resection because of the difficulty of
isolating and culturing mycobacteria in vitro. Twenty-two patients
had one previous operation, 3 patients had two previous opera-
tions, and 1 patient had three previous operations. Two of the
patients also had previous thoracoplasty. Only 2 of the 26 patients
had the initial operation performed at the University of Colorado
Hospital. The interval between previous operation and completion
pneumonectomy was 3 months to 46 years, with a mean interval of
12.7 years.
Infecting organisms were Mycobacterium avium complex in 15
patients, multidrug-resistant Mycobacterium tuberculosis in 4,
nonresistant M tuberculosis in 1, Mycobacterium xenopi in 2,
Mycobacterium chelonae in 1, Mycobacterium abscessus in 1, and
both M chelonae and M abscessus in 2. Eleven of the patients had
polymicrobial infection, with Aspergillus species in 8, Pseudomonas
species in 2, and Klebsiella species in 1. Sixty-five percent of the
patients had sputum positive for mycobacteria at the time of
operation.
Significant comorbidities were present in 85% of the patients
TABLE 1. Comorbidities in patients undergoing completion
pneumonectomy
Condition No. %
Anemia 20 77
Smoking history (15 pack-years) 15 58
Obstructive pulmonary disease 9 35
Restrictive pulmonary disease 10 34
Steroid use 4 15
Asthma 3 12
Restrictive and obstructive
pulmonary disease
2 8
Coronary artery disease 1 4
Diabetes 0 0and are summarized in Table 1. Many patients had bronchiectasis,
The Journal of Thoraciceither primary or secondary to the chronic mycobacterial disease.
The average serum albumin level at the time of operation was 3.1 
0.66 g/dL (range 2.2-4.7 g/dL). Seventy-seven percent of the pa-
tients were below ideal body weight, and 50% of these patients
were more than 10% below ideal body weight. These values
represent body mass after 2 to 3 months of aggressive nutritional
supplementation. The average hemoglobin level was 11.1  2.2
g/dL (range 8.0-18.2 g/dL), with most patients having a diagnosis
of anemia of chronic disease.
Indications for operation are listed in Table 2. Almost all the
patients had persistent fevers, weight loss, and general failure to
thrive. Lung destruction or cavitary disease was present in all
cases, with chronic obstructive or restrictive pulmonary disease a
common underlying problem. In 5 cases, the presence of a BPF
was the primary indication for completion pneumonectomy.
Chronic hemoptysis was present in several patients; however, it
was the primary indication for operation in only 1 case. No patients
had massive hemoptysis. Treatment consisted of a multidisci-
plinary approach, with involvement of thoracic surgeons, infec-
tious disease specialists, pulmonologists, a nutritionist, and a phys-
ical therapist. Weekly multidisciplinary conferences were used to
plan and reevaluate ongoing therapy. Patients underwent chest
radiography, computed tomography, pulmonary function testing,
split function perfusion testing, and bronchoscopy.
Patients received at least 2 to 3 months of preoperative anti-
microbial therapy in an attempt to convert sputum to a negative
status or to decrease the bacterial count in the sputum. All patients
were treated with aggressive, individualized antibiotic therapy on
the basis of in vitro drug susceptibility testing; however, none of
the 18 patients with positive sputum had conversion to a negative
status. The mycobacterial count usually reached a nadir after 3
months of therapy, and surgical intervention was then performed.
Sputum specimens were collected bronchoscopically to ensure
adequate sampling and decrease the likelihood of contamination.
Antimicrobial therapy was continued, typically for 2 years post-
operatively, on the basis of the status of serial sputum collections.
At the time of initial evaluation, a complete nutritional assess-
ment was made, and aggressive nutritional supplementation com-
menced. One of the patients in this group received a preoperative
feeding gastrostomy, and another received a nasojejunal tube. All
patients who had poor preoperative oral intake were strongly
encouraged to have feeding tubes placed at the time of surgery;
TABLE 2. Indications for undergoing completion
pneumonectomy
Condition No. %
Destroyed lung 24 92
Cavitary disease 22 85
Constitutional symptoms
(fevers, weight loss)
21 81
Persistent positive sputum 17 65
Hemoptysis 9 35
BPF 5 19
Antibiotic intolerance 2 8
Bronchial stenosis 1 4however, only 3 consented to have this performed. With close
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during the preoperative antibiotic course. Our experience with
these patients has been that few actually gained weight as a result
of their chronic catabolic state. Despite good caloric intake under
the supervision of a dietician, little weight gain was observed. This
finding may, however, have been related to lack of adequate
feedings in these patients.
Preparation for surgery also involved evaluation with chest
radiography, contrast-enhanced computed tomography, bronchos-
copy, pulmonary function testing, and ventilation and perfusion
scintigraphy. Echocardiography was also performed, and right
heart catheterization was performed if there was evidence of
pulmonary hypertension. Patients were selected for completion
pneumonectomy according to the requirement of a postoperative
forced expiratory volume in 1 second (FEV1) greater than 800 mL.
The mean preoperative FEV1 was 1.54  0.43 L (0.88-2.84 L),
and the mean perfusion values of the operated side were 15.8%
(range 0%-30%) for left-sided resections and 17.8% (range 0%-
36%) for right-sided resections. The average postoperative pre-
dicted FEV1 values were 1.39 L (range 0.82-2.2 L) for left-sided
resections and 1.25 L (range 0.60-2.1 L) for right-sided resections.
Anesthetic and Analgesic Considerations
Surgical resection was performed with the patient under general
anesthesia with a double-lumen endobronchial tube or a standard
endotracheal tube with a bronchial blocker. Endobronchial sepa-
ration is critical to prevent pooling of purulent secretions into the
dependent healthy lung during the operation. Bronchoscopy was
performed to clear the airways of any mobile secretions. Epidural
catheters were placed in all patients. Ketorolac tromethamine (INN
ketorolac) was also administered and was given postoperatively
for as long as 72 hours. We have found orally administered
low-dose benzodiazepines to be helpful in reducing the degree of
postoperative pain and the need for narcotics in these patients.
Surgical Technique
All mycobacterial antibiotics were administered the morning of
surgery, and intravenous cefazolin was administered before skin
incision. A posterolateral thoracotomy was performed on all pa-
tients, usually following the line of the previous incision scar. In
many cases, the latissimus dorsi muscle (LDM) had been at least
partially divided at the previous operation. We made every attempt
to salvage this muscle because of the excellent mediastinal cover-
age it provides. The LDM was detached from its insertion on the
chest wall. The serratus anterior was spared. The fifth or sixth rib
was then resected as far medially as possible, which not only
facilitated exposure but also helped to define the extrapleural
plane. The intercostal muscle pedicle was carefully preserved for
later use as a buttress for the bronchial stump. In several cases, no
muscle was available for coverage, and omentum therefore was
harvested through an upper midline abdominal incision. The
omentum was carefully divided, with care to avoid injury to the
gastroepiploic vessels, with the blood supply based on the right
gastroepiploic artery. The omentum was tagged with a heavy silk
and then brought up toward the pleural space at the junction of the
anterior chest wall and the diaphragm. After the lung was resected,
the anterior diaphragm was traversed and the omentum was
retrieved.
1260 The Journal of Thoracic and Cardiovascular Surgery ● JunOnce the thoracic cavity was entered, adhesions were carefully
taken down. In 20 patients, the inflammatory process had eroded
into the chest wall, and partial dissection of the chest wall was
performed in a deep extrapleural plane. In the apex of the pleural
space, one must take care to avoid injury to the subclavian vessels,
especially given the poor visibility in this area. If lung tissue is
densely adherent, it is better to leave some lung parenchyma
behind than to risk vessel injury. Dissection along the mediastinum
was performed, identifying the pulmonary artery and vein. In cases
where a previous left or right upper lobectomy had been per-
formed, the inferior vein was isolated and divided extrapericardi-
ally. The remaining left superior or right superior vein was then
isolated and divided intrapericardially, which in turn facilitated
intrapericardial identification, isolation, and division of the pulmo-
nary artery. If intrapericardial dissection was not possible because
of excessive adhesions, the bronchus was controlled and divided
first, and then the vessels were controlled with this improved
exposure. The right pulmonary artery was usually controlled by
dissection under the superior vena cava or between the aorta and
the superior vena cava. If a previous lower lobectomy had been
performed, then extrapericardial dissection and isolation of the
vessels was usually possible. Vessels were divided with a vascular
stapling device. In patients with a contaminated pleural cavity for
whom an Eloesser procedure was planned, if dense inflammatory
tissue was present on the mediastinum, this tissue was left to be
débrided with dressing changes. The argon beam coagulator was
routinely used to control the diffuse bleeding from the chest wall
after the dissection was completed.
Management of the Bronchial Stump
The bronchus was closed with a TA-30 4.8-mm stapler (United
States Surgical Corporation, Auto Suture Company Division,
Norwalk, Conn) in all but 1 case. In that single patient, the right
lateral trachea was torn during the dissection and was repaired and
closed with interrupted 3-0 Prolene suture (Ethicon, Inc, Somer-
ville, NJ). The bronchial stump was reinforced with LDM in 14 of
the patients (54%), with intercostal muscle in 3 (12%), and with
omentum in the remaining 9 (35%). The LDM was brought into
the chest cavity through a defect in the chest wall created by
resection of the third or fourth rib and then sutured around the
bronchus and mediastinal structures with absorbable suture. Sim-
ilarly, the intercostal muscle or omentum was tacked down around
the bronchus and mediastinal structures. We always interposed
muscle between the pulmonary artery and the bronchial stump.
Management of the Pleural Space
Patients who had frank purulent material or heavy contamination
in the pleural space underwent an Eloesser procedure during the
same operative session. This was performed by resecting two to
three ribs at the medial aspect of the thoracotomy. All the skin was
preserved, and the epithelialized tract was fashioned by turning
down the upper portion of the flap with interrupted sutures of 2-0
nylon fiber. The ribs laterally and remaining soft tissues were then
approximated. The cavity was packed with dilute povidone-iodine–
soaked Kerlix gauze (The Kendall Company, Mansfield, Mass).
After the bronchial stump reinforcement was completed, 2 L of
cefazolin-containing solution was used to irrigate the pleural cav-
ity, and a Pulsevac was used if there was heavy soilage. No
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600 to 700 mL of air was aspirated from the pleural space once the
skin was closed.
Intraoperative blood loss was carefully recorded and replaced
1:1 with packed red blood cells and colloid in the form of 5%
albumin or fresh-frozen plasma. This practice appears to decrease
the crystalloid requirement and also the amount of third-spacing
postoperatively. No autotransfusion devices were used, because
we believe that autotransfusion may promote bacteremia and sep-
sis syndrome.
After completion of the procedure, thorough toilet bronchos-
copy was performed, because it is common for secretions from the
diseased lung to pool into the dependent remaining lung. The
patient was then extubated in the operating room and transported
to the surgical intensive care unit, where careful postoperative
monitoring was performed for 24 to 48 hours. All patients were
given supplemental oxygen therapy to maintain a pulse oximeter
oxygen saturation of 90% to 92%. Intravenous cefazolin was
continued for 24 hours, and all mycobacterial medications are
continued throughout the hospital course. Aggressive pulmonary
toilet was performed; this included incentive spirometry and
Acapella valve (DHD Healthcare, Wampsville, NY) therapy, as
well as percussive chest physiotherapy three to four times daily.
Respiratory therapists dedicated to the thoracic service served
these patients in the intensive care unit and on the thoracic surgery
ward. Patients were fluid restricted to 1500 mL/d, and diuretic
therapy was administered to maintain a negative fluid balance.
Patients were out of bed for several hours during the day, and
ambulation was started on postoperative day 1 with the aid of
physical and occupational therapists. Aggressive nutritional sup-
port was continued postoperatively with oral supplements and, if
necessary, nasoduodenal feeding tubes.
Patients with Eloesser flaps had the dressing removed on post-
operative day 2, and subsequent dressing changes were performed
every 2 days with half-strength Dakin solution–soaked Kerlix
gauze. After discharge, these patients then returned to the Univer-
sity of Colorado Hospital for closure of the Eloesser, which was
performed after 4 to 6 weeks, depending on the degree of contam-
ination and the presence of granulation tissue. We débrided any
tissue that appeared to be infected or covered with eschar. The
edges of the thoracostoma were débrided to healthy bleeding tissue,
and the soft tissue planes were dissected. From 500 to 1000 mL of
Clagett solution was placed into the pleural cavity, and the skin
edges were approximated in a watertight fashion with a deep layer
of absorbable suture followed by interrupted cutaneous nylon
sutures, which were left in place for 3 to 4 weeks. Patients could
be then be discharged the same day or within 24 hours of surgery.
Patients were continued on their mycobacterial medication regi-
mens for as long as 2 years, with periodic sputum sampling.
Results
Operative Details
Operative time ranged from 114 minutes to 400 minutes, with
a mean operative time of 253  82 minutes. The mean esti-
mated blood loss during the procedure was 1090  832 mL
(range 350-4000 mL). Perioperative blood transfusions av-
eraged 3.77 units per patient (range 0-14 units), and the
The Journal of Thoracicoverall blood transfusion rate was 92%. Reexploration for
persistent postoperative bleeding did not occur. Intraopera-
tive complications included a laceration of the left atrium in
1 patient, a tear in the pulmonary artery in 1 patient, and a
tracheal injury in 2 patients; both tracheal injuries were
repaired primarily. One patient underwent a splenectomy
after spleen injury during taking down of the omentum.
Most patients had extrapleural dissections with heavy in-
flammatory involvement of the apex of the lung.
Mortality
There were no intraoperative deaths. There were 6 postop-
erative deaths during the initial hospitalization, 4 of which
occurred within 30 days of the operation, (mortality 23%).
Two patients, 1 of whom had preexisting pulmonary hyper-
tension, died of adult respiratory distress syndrome. Other
causes of in-hospital mortality included BPF with subse-
quent pneumonia and multisystem organ failure, pulmonary
embolus, Aspergillus species sepsis with multisystem organ
failure, and sepsis-related complications.
There were two late (90 days) outpatient deaths. One
was that of a patient who, after treatment for a BPF, was
discharged to a nursing home in another state and died 2
weeks later of unknown causes. Another was that of a
patient discharged home after an uneventful postoperative
course who died of unknown causes 2 months later.
Morbidity
Complications after completion pneumonectomy were en-
countered in 12 patients (46%), and the incidences of these
complications are summarized in Table 3. Respiratory fail-
ure was defined as ventilator dependence longer than 24
postoperative hours, need for reintubation, or need for non-
invasive positive-pressure ventilation. One patient had an
uncomplicated myocardial infarction. The patients who had
atrial arrhythmias develop were rate controlled and had no
TABLE 3. Postoperative morbidity after completion
pneumonectomy
Complication No. %
Bronchopleural fistula 7 27
Respiratory failure 5 19
Pneumonia 5 19
Arrhythmia 3 12
Adult respiratory distress syndrome 2 8
Deep vein thrombosis 2 8
Wound complication 2 8
Myocardial infarction 1 4
Empyema without bronchopleural fistula 0 0
Postoperative bleeding necessitating
thoracotomy
0 0hemodynamic instability. There were 2 seromas that formed
and Cardiovascular Surgery ● Volume 129, Number 6 1261
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required no intervention and resolved spontaneously. There
were no empyemas independent of a BPF. Two patients had
subclavian vein thrombosis develop at the site of a periph-
erally inserted central catheter; 1 of them died of a pulmo-
nary embolus.
BPFs developed in a total of 7 patients, 4 early (30
days) and 3 late (range 2-17 months). Three of the 4 patients
in the early group died, and there were no deaths in the late
group. Of the 7 patients, 5 had positive sputum at the time
of operation. All the BPFs were on the right side, and all had
stapled bronchial closure with LDM flap coverage. Two of
the early BPFs occurred in patients who had been intubated
for pneumonia. The other 2 occurred in patients with
polymicrobial infections, 1 of whom had a postoperative
predicted FEV1 of 0.6 L and severe malnutrition with an
albumin of 2.2 g/dL. Among the patients with late BPFs, 1
patient was receiving long-term steroid therapy, 1 was
chronically malnourished, and the other had a relatively
uncomplicated postoperative course except for uncompli-
cated pneumonia.
Early BPFs were initially managed with a chest tube.
Five patients underwent either transmediastinal closure with
a sternohyoid muscle flap or transthoracic closure with a
revised LDM flap. An Eloesser thoracostoma was per-
formed at the same time, and a Clagett procedure was
performed 4 to 6 weeks later for the patients who survived.
One patient underwent transbronchial bioglue closure,
which eventually broke down; this patient died in a nursing
Figure 1. Actual survival of patientshome on postoperative day 86. The patient who did not have
1262 The Journal of Thoracic and Cardiovascular Surgery ● Juna fistula closure performed had early multisystem organ
failure develop, and support was withdrawn.
Five patients underwent Eloesser procedures at the time
of the initial surgery; 4 of them had a BPF as an indication
for completion pneumonectomy. Three of these patients
were long-term survivors and returned 4 to 6 weeks after
discharge for a Clagett procedure. Among the patients who
survived past hospital discharge, the median stay was 7.5
days (range 3-99 days). The overall actual survival was 54%
(Figure 1), and the 3 deaths that occurred longer than 6
months postoperatively were all consequences of respira-
tory failure. Of the 17 long-term survivors, 14 had conver-
sion of sputum to negative or were able to stop taking
mycobacterial antibiotics.
Discussion
Disease caused by mycobacteria can be classified into in-
fection with M tuberculosis and environmental mycobacte-
ria (EM). EM includes M avium complex, M xenopi, and
Mycobacterium kansasii, as well as rapidly growing organ-
isms such as M abscessus, Mycobacterium fortuitum, and M
chelonae. The incidence of M tuberculosis infection had
been increasing in the United States, with more than 50,000
excess cases reported during the period between 1985 and
1992.1 During the past 10 years, these numbers have de-
clined slowly, but in 2003 there were still a total of 14,871
M tuberculosis cases reported in the United States. Despite
this overall decline, M tuberculosis continues to be a prob-
lem in certain areas of the country, where rates have in-
rgoing completion pneumonectomy.undecreased in such populations as foreign-born persons and
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the proportion of multidrug resistant tuberculosis cases and
in the number of young persons infected. The HIV epidemic
has resulted in an increasing number of persons at risk for
reactivation of latent tuberculosis.3
EM are free-living bacteria that have been recovered
from surface and tap water, soil, domesticated animals,
inanimate objects, and food products. Transmission to hu-
man beings is likely through inhalation or oral ingestion.
These organisms most commonly cause pulmonary infec-
tion in immunocompromised patients or in those with pre-
existing lung disease. Another group of individuals with a
high incidence of EM pulmonary infection is that of thin,
middle-aged, nonsmoking white women with midlung field
nodular bronchiectasis.4,5 Because of the lack of human-to-
human transmission, the epidemiology in not completely
known; however, there may be as many as 3000 new M
avium complex cases annually, and this incidence may be
increasing.6
There is a general consensus regarding drug therapy for
tuberculosis. However, there is a paucity of data regarding
optimal drug treatment for EM. Drugs used to treat EM
infections include clarithromycin and azithromycin, ri-
fampin (INN rifampicin), ethambutol, aminoglycosides,
fluoroquinolones, cycloserine, clofazimine, ethionamide,
and isoniazid. At National Jewish Medical and Research
Center in Denver, Colorado, combinations of these drugs
are used according to in vitro susceptibility testing and
therapeutic drug monitoring to optimize efficacy and reduce
toxicity. The duration of therapy is typically 24 months,
because shorter treatment periods have been associated with
an increased risk of relapse.7
Medical therapy for mycobacterial disease has progres-
sively improved during the last several decades. With the
increasing numbers of patients with multidrug-resistant M
tuberculosis and EM infections, however, surgical therapy
is becoming more common. Because of the indolent nature
of EM disease, patients undergoing surgery typically have
more extensive parenchymal destruction, and this in turn
promotes a spiraling deconditioned preoperative status. In
this study, 77% of the patients were below their ideal body
weight, and 77% also had anemia. Despite aggressive nu-
tritional supplementation, the average preoperative albumin
level was still only 3.1 g/dL. This deficiency, coupled with
significant underlying lung disease, puts these patients at
high risk for complications. We have considered even more
aggressive nutritional supplementation with feeding tubes
for all patients with malnutrition (gastrostomy tubes or
nasojejunal tubes); however, many patients refuse feeding
tubes or do not tolerate them.
Resectional therapy is considered when patients have
localized, extensive damage to the lung parenchyma or
airways, which is considered to predispose toward treatment
The Journal of Thoracicfailure.7 Indications for surgery include cavitary disease,
destroyed lung tissue, continued sputum positivity despite
maximal drug therapy, chronic hemoptysis, BPF, and bron-
chial stenosis. Most patients have several of these charac-
teristics. Almost all these patients have constitutional symp-
toms such as fevers, malaise, weight loss, and general
failure to thrive. Of significant concern is the potential
contamination of relatively healthy contralateral lung paren-
chyma. Surgical intervention should be performed before
spillage of bacteria occurs with further respiratory
deterioration.
Resectional therapy for TB and EM disease has been
described by us and others. We have had favorable out-
comes for patients undergoing primary resectional therapy,
with excellent operative morbidity and mortality and high
rates of sputum conversion. This has been shown in patients
with middle lobe and lingular disease,8 as well as patients
with multidrug-resistant M tuberculosis.9 Primary or com-
pletion pneumonectomy for any benign disease carries with
it significant morbidity and mortality. Reed and col-
leagues10 described their experience with pneumonectomy
in 13 patients with chronic pulmonary infection, including 2
patients with mycobacterial disease. Although the perioper-
ative mortality was only 7.6%, they reported significant
morbidity, such as long operative times with large operative
blood loss, as well as a BPF rate of 23%. Other groups have
also reported significant morbidity, with higher rates of
intraoperative bleeding, empyema, and BPF when primary
pneumonectomy is performed for sequelae of tuberculo-
sis.11,12 Our early experience with primary pneumonectomy
for mycobacterial disease also demonstrated a higher risk
for BPF and mortality, particularly among patients with
EM. This may be due to the more indolent nature of these
infections, which leads to more profound chronic malnutri-
tion and immune system compromise. These patients also
tend to be older and have more comorbidities than patients
with tuberculosis.
Completion pneumonectomy is associated with even
higher morbidity and mortality, particularly when per-
formed for benign or infectious disease. Several large series
have documented mortalities as high as 27.6%, as well as
higher rates of cardiopulmonary morbidity and other major
complications.13-15 Chronic inflammation and fibrosis, par-
ticularly in the hilum, make the surgical procedure techni-
cally demanding, and distorted tissue planes increase oper-
ative times. Routine intrapericardial dissection and vessel
ligation probably reduce the incidence of exsanguinating
hemorrhage; however, the usual requirement for an ex-
trapleural dissection makes blood loss more significant.
Although there were no deaths from exsanguinating hem-
orrhage, 93% of our patients required blood transfusion,
potentially increasing morbidity and mortality.13
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monectomy, and various reports in the thoracic surgery
literature report incidences of 0% to 23%, with a higher
occurrence when the operation is performed for benign
disease.10,16 Demonstrated risk factors for BPF include right
pneumonectomy, postoperative mechanical ventilation,17
the presence of chronic obstructive pulmonary disease, poor
postoperative FEV1, lack of bronchial stump coverage,18
and perhaps the presence of pleuropulmonary infection.17 In
this series, we had 7 BPFs, all of which were right sided,
and most affected patients had at least one of these defined
risk factors. We learned in our previous experience that the
use of muscle or tissue flaps to buttress the bronchial stump
led to a decrease in the rate of persistent air leaks and
possibly BPFs in primary lobar resection for mycobacterial
disease. However, we had a BPF rate of 47% in our early
experience with pneumonectomy for EM infection, despite
the use of muscle coverage.8 Other groups have reported the
benefits of using autologous tissue for bronchial stump
coverage in pneumonectomy for cancer and benign dis-
ease13,18,19 which may also potentially reduce the incidence
of BPF.20 Repair of BPF with autologous tissue has been
shown to be beneficial in several studies21,22 and is routine
in our practice. We avoid using the serratus anterior for any
muscle flap because of the complications of shoulder girdle
dysfunction and winged scapula–related problems with
wound healing and skin necrosis. Because of our incidence
of BPF with LDM coverage, we now try always to use
omentum for bronchial stump coverage, particularly in
right-sided resections. Additionally, we have recently
changed our practice and instead of using a stapled bron-
chial closure, we now perform a tailored suture closure.
Postpneumonectomy empyema, a complication that is
usually life-threatening, was not observed in any of our
patients. Our aggressive use of an Eloesser flap at the time
of completion pneumonectomy probably prevented this
from occurring. The Eloesser is well tolerated by the pa-
tients, and an experienced nursing staff is helpful in facili-
tating dressing changes and educating the patients and their
families. Appropriate analgesic techniques make this expe-
rience tolerable. We continue dressing changes for 4 to 6
weeks postoperatively, until the space is clean and granu-
lating, and do not routinely use tissue culture results when
deciding to close the Eloesser. Patients are generally dis-
charged within 24 hours of surgery, and we have not seen
any complications in this group of patients.
Another important aspect of the care of these patients is
aggressive pulmonary toilet. Early mobilization, coughing
and deep breathing exercises are facilitated by the routine
use of epidural catheters (despite the infected nature of the
cases, we have not seen an infected epidural catheter in any
or our patients with mycobacterial infection). Nebulizer
therapy with chest physiotherapy by experienced respiratory
1264 The Journal of Thoracic and Cardiovascular Surgery ● Juntherapists and hourly incentive spirometer and Acapella
valve use by the patients help to prevent secretion pooling,
atelectasis, and consequent pneumonia.
Completion pneumonectomy is an important component
of therapy for patients with chronic mycobacterial disease.
Although associated with high morbidity and mortality,
careful patient selection and a well-organized multidisci-
plinary approach can optimize clinical outcomes. Patients
infected with EM tend to have the most problems because of
the indolent nature of the disease, and many become se-
verely debilitated. Most of these patients are unable to work,
posing significant burdens for their friends, families, and
society. Resectional therapy may be the only hope for many
of these patients, who are essentially dying slowly of their
disease.
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Discussion
Dr Douglas Wood (Seattle, Wash). I congratulate Sherwood and
colleagues for a well-analyzed series and a well-presented article.
Pomerantz, Mitchell, and their group at the University of Colorado
have long been leaders in the surgical care and the scientific
evaluation of patients with complex mycobacterial infection. This
article looks at the worst of the worst: completion pneumonectomy
for infectious disease, a procedure fraught with technical difficulty
and high morbidity and mortality. I must admit my deepest respect
for the amount of work that Sherwood and colleagues have in-
vested in caring for these patients and my admiration for their
superb results. However, one cannot help but still note a formidable
mortality of 31% and a BPF rate of 27%, even in the experienced
hands of the Colorado team. I urge anyone, including myself, con-
templating completion pneumonectomy in this patient group to con-
sider referral to Colorado, or at least to follow the methodical and
carefully outlined treatment plan presented in the published article. Dr
Sherwood, I would like to ask you three questions.
First, are there any lessons to be learned when you analyze the
patients who died or didn’t have conversion of their sputum after
surgery? Are there certain patterns of disease or certain organisms
that we should consider as contraindications for surgery despite the
poor prognosis with medical therapy?
Dr Sherwood. We previously published data that show that
patients with mycobacteria other than tuberculosis or the environ-
mental bacteria that most patients in the study had do probably
face a higher mortality than patients who have M tuberculosis. In
the same vein, these patients probably have a higher risk for BPF.
These patients are extremely debilitated, and we are starting to
realize—we have actually realized this for many years now but are
starting to take more seriously—the debilitated nature of these
patients and how malnourished they are. I think one of the things
we can change is providing prolonged nutritional support for these
patients before they go to surgery. Some of the patients that died
had very low albumin levels. Some were very low weight and had
very poor functional status.
Dr Wood. So we’ll still operate on them, we’ll just prepare
them better.
Dr Sherwood. That’s right.
Dr Wood. Second, it has long been known that right pneumo-
nectomy, completion pneumonectomy, and infectious indication
are all risk factors for BPF, and that is three strikes in this patient
population I guess. With a nearly 50% incidence of right-sided
BPF in your series, would you consider changing your technique
The Journal of Thoracicand doing a hand-sewn closure of the stump rather than a stapled
closure? I detect from the later phase of your series that you have
changed your technique in terms of providing an omental soft-
tissue flap rather than LDM. What about your bronchial stump
closure in those cases?
Dr Sherwood. I don’t think there are any data to support
closure with a stapling device versus a hand-sewn suture technique
in prevention of BPF. We have always used the stapling device, at
least for the past 10 years, and we have had pretty good results in
our other sets of patients. I think that the key to preventing BPF in
these patients is using an omental flap. I think it provides excellent
tissue coverage. It is pliable and incorporates into the interstices of
the hilum better, and I think it also promotes angiogenesis and
bronchial stump healing, so I think that is the main thing that we
are going to change on the basis of the results of this study.
Dr Wood. Well, we may have a difference of opinion regard-
ing the best way to close right-sided bronchial stumps. Finally,
how do you decide between using omentum versus LDM? It
sounds as though although you used LDM a lot early in your
series, you have become progressively disillusioned with the LDM
and are leaning more and more toward omentum. How do you
differentiate when to use which?
Dr Sherwood. I think in this situation, given the fact that these
patients have had a previous thoracotomy and most of them have
some degree of division of the LDM, we always look at it after we
harvest it and look at the viability of the distal portion of it. Even
though it may look viable, there is probably some diminished
blood flow and some fibrosis, and it probably doesn’t provide what
we think is good coverage and healing potential for the stump. I
think that especially in this group of patients the use of omentum,
which is technically not difficult but is more time consuming, will
be the way we do these in the future.
Dr Peter Pairolero (Rochester, Minn). Clearly, this is a very
difficult group of patients to manage, and each patient is an
individual, with probably not a lot of similarity to the following or
preceding patient. A point I want to make, though, is that almost
all these patients have an infected thorax, and one of the difficulties
of doing an omental operation is that you have to open up a sterile
visceral cavity. That leads to the possibility of infection into the
abdomen. In addition to that, you have to create some sort of
hernia to get the omentum out of the belly. You either have to
create an incisional hernia or you have to create a diaphragmatic
hernia. I would like to offer another alternative, the serratus
anterior muscle. In my experience, which is extensive, almost
never is the serratus anterior muscle transected, and if it is
transected, it’s always transected in the lowest part. I have used the
serratus anterior in preference to the LDM because the LDM is
often not a good muscle, because it has been in a previous
thoracotomy. But I would make the plea that the serratus anterior
is better than the omentum for the reasons that I just enumerated.
Dr Sherwood. We used to use the serratus more often than we
do now. One of the problems we have with these patients is that
because they are so malnourished and debilitated, we have had
problems with the wing scapula and that impairing the wound
healing along the incision in that area. So we have kind of gotten
away from using the serratus, but I agree that it is a handy muscle
to use, and we may use it in certain situations.
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